对于晚期皮肤T细胞淋巴瘤的罗米德素和莫加穆利祖马布连续治疗
Emily R Gordon1, Seda Tolu2, Brigit A Lapolla3
1Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Leukemia & lymphoma
|August 11, 2025
概括
用罗米德素和莫加穆利祖马布进行序列治疗对晚期皮肤T细胞淋巴瘤 (CTCL) 显示出有前途. 与单剂疗法相比,这种组合疗法改善了反应率和延长了下一次治疗的时间.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 晚期皮肤T细胞淋巴瘤 (CTCL) 提出了管理挑战,具有有限的持久反应和当前疗法显著的毒性.
- 罗米德素和莫加穆利祖马布作为单一疗法显示出有效性,但整体生存结果仍然不理想.
研究的目的:
- 评估在晚期CTCL患者中连续进行罗米德素-莫加穆利祖马布治疗的有效性.
- 将顺序治疗的结果与历史单一治疗数据进行比较.
主要方法:
- 对18名患有晚期CTCL的患者进行了回顾性分析,这些患者接受了序列性罗米德素治疗,随后接受了莫加穆利祖马布治疗.
- 评估整体反应率 (ORR) 和时间到下一次治疗 (TTNT).
主要成果:
- 连续的罗米德素-莫加穆利祖马布疗法实现了67%的整体响应率.
- 到下一次治疗的时间为15个月,与单一治疗的临床试验相比较有利.
- 在停止使用罗米德辛后,迅速过渡到莫加穆利祖马布与皮肤,血液和淋巴结的优异反应以及更长的TTNT相关.
结论:
- 连续的罗米德素-莫加穆利祖马布疗法在晚期CTCL中显示出潜在的益处,特别是在密切连续使用时.
- 这些发现表明罗米-莫加序列具有有利的影响,需要进一步调查.
- 需要进行前性研究来证实这些结果,并优化高级CTCL的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


